Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2004
Business Overview: Alcon is a global medical specialty company focused on eye care, developing, manufacturing, and marketing pharmaceuticals, surgical equipment/devices, and consumer eye care products. The company operates through two segments: Alcon United States and Alcon International. As of December 31, 2004, Nestlé S.A. owned approximately 75% of Alcon's outstanding common shares.
Key Financial Metrics (Year Ended Dec 31, 2004)
| Metric | 2004 (in millions) | 2003 (in millions) |
|---|---|---|
| Sales (Revenue) | $3,913.6 | $3,406.9 |
| Gross Profit | $2,832.0 | $2,401.0 |
| Gross Margin | 72.4% | 70.5% |
| Operating Income | $1,131.8 | $879.4 |
| Operating Margin | 28.9% | 25.8% |
| Net Earnings | $871.8 | $595.4 |
| Diluted EPS | $2.80 | $1.92 |
| Operating Cash Flow | $1,047.8 | $915.4 |
| Total Debt | $988.0 | $1,410.3 |
| Cash & Equivalents | $1,093.4 | $1,086.0 |
| Net Cash Position | $105.4 | ($324.3) |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 14.9% to $3.91 billion. Excluding foreign exchange impacts, sales grew 11.1% in constant currency, driven by volume growth in the U.S., Japan, Brazil, and Europe.
- Profitability Expansion: Operating income rose 28.7% to $1.13 billion. Net earnings surged 46.4% to $871.8 million. This was driven by a 18.0% increase in gross profit and a significant $57.6 million current tax benefit from amended tax returns and audit resolutions.
- Product Performance:
- Pharmaceuticals: Sales grew 17.8% (14.9% constant currency), led by glaucoma (Travatan) and anti-infectives (Vigamox).
- Surgical: Sales grew 14.4% (9.7% constant currency), driven by cataract equipment (Infiniti system) and intraocular lenses, offset by a 10.7% decline in refractive equipment sales.
- Consumer Eye Care: Sales grew 8.9% (5.6% constant currency), with strong growth in artificial tears (Systane).
- Liquidity Improvement: The company reduced short-term borrowings by $434.5 million, improving its net cash position from a net debt of $324.3 million in 2003 to a net cash position of $105.4 million in 2004.
Guidance, Outlook, and Risks
- Dividend Outlook: Management expects to declare a 2004 dividend of CHF 1.18 per share (approx. $1.00), totaling an estimated $305 million, subject to shareholder approval in May 2005.
- Product Pipeline: Key developments include the FDA submission for RETAANE (wet AMD treatment), though Phase III results were not as strong as anticipated. The company plans to file for AcrySof Natural Toric lenses and expand CustomCornea indications for hyperopia in 2005.
- Accounting Changes: Adoption of SFAS No. 123(R) regarding share-based payment is expected in Q3 2005, estimated to decrease pretax earnings by approximately $28 million.
- Key Risks:
- Regulatory & Pricing: Pressure from third-party payors, government price controls (especially in Japan and EU), and potential OTC switching of prescription drugs.
- Currency: Significant exposure to the Euro, Japanese Yen, and Swiss Franc; a strengthening U.S. dollar negatively impacts reported sales.
- Supply Chain: Reliance on single-source suppliers for active ingredients and single-source manufacturing facilities for key products.
- Insurance: Effective March 31, 2005, the company will self-insure almost all property, casualty, and liability risks, discontinuing third-party coverage.
Investor Verification Checklist
- Dividend Approval: Confirm shareholder approval of the proposed CHF 1.18 dividend at the May 3, 2005 annual meeting.
- Tax Benefit Sustainability: Verify if the $57.6 million tax benefit in 2004 was a one-time event (amended returns/audit resolution) and assess the impact on future effective tax rates.
- Refractive Surgery Demand: Monitor trends in elective laser refractive surgery, which is sensitive to economic conditions and showed a sales decline in 2004.
- RETAANE Development: Track the status of the RETAANE Phase III clinical trials for wet AMD, given the mixed results reported.
- Self-Insurance Exposure: Review the company's risk management strategy following the decision to self-insure property and liability risks starting March 31, 2005.
- Stock-Based Compensation: Assess the impact of the upcoming adoption of SFAS 123(R) on reported earnings in 2005.